About Marc

Dr. Bulterys became Team Leader of the Global Hepatitis Programme at WHO-Geneva on Sept 1, 2016 (seconded by the U.S. Centers for Disease Control and Prevention (CDC) Division of Viral Hepatitis). In this WHO position, Dr. Bulterys provides scientific expertise and coordinates global technical activities related to viral hepatitis prevention and control. From 2013-2016, he was Associate Director for Science at the Naval Health Research Center in San Diego. From 2008-2013, he served as Director of the CDC Global AIDS Program in Beijing, China. From 2004–2008, he served as CDC Country Director in Lusaka, Zambia. He also served on detail as CDC Director in Haiti in 2011 during the cholera outbreak response; and CDC Ebola Response Lead in Guinea in Fall 2015. From 1998-2004, he was medical officer and team lead in the Epidemiology Branch, overseeing research on perinatal/pediatric HIV, including viral co-infections. He is currently in his 19th year with CDC.
Prior to CDC, he was a fellow at the Viral Epidemiology Branch, U.S. National Cancer Institute, and a faculty member at the University of New Mexico School of Medicine. During this time, his primary research focus was on viral hepatitis. Marc also worked in Butare, Rwanda (1989-1993) for Johns Hopkins University. Dr. Bulterys is (co)author of 150+ peer-reviewed articles and 2 books. He received the Kellie Lartigue-Ndiaye Global Humanitarian Award and the Shepard Science Award at CDC. Dr. Bulterys received his M.D. training at the University of Leuven, Belgium, and a Ph.D. in epidemiology (minor in immunology and microbiology) as a Fulbright Scholar at the University of California at Los Angeles (UCLA).

This speaker will be presenting at the following session(s)

  • Strategic direction 1: strategic information for focused action

    Golden Hall

    Day: 1 November

    Time: 13:30

    The Summit’s agenda takes the Global Health Sector Strategy on Viral Hepatitis (GHSS) - and its 5 strategic directions - as its framework. In this plenary session, strategic direction 1 looks at advocacy, political commitment and national planning.

    Chairs: Dr. Leolin Katsidzira, University of Zimbabwe College of Health Sciences and Tatjana Reic, European Liver Patients’ Association


    • Global viral hepatitis situation and response.

      Dr. Marc Bulterys, World Health Organization

    • WHO country profiles report.

      Prof. Sharon Hutchinson, Glasgow Caledonian University, UK

    • The power of people: integrating civil society in the global hepatitis response.

      Charles Gore, World Hepatitis Alliance

    • The role of liver societies in the global viral hepatitis response.

      Anna Lok, American Association for the Study of Liver Diseases

    • Country level experience of using strategic information to inform their national hepatitis response. 
      Zimbabwe - Rapid assessments: Dr. Leolin Katsidzira, University of Zimbabwe College of Health Sciences
      Vietnam - Hepatitis surveillance: Dr. Tran Dai Quang, Ministry of Health, Viet Nam
    • Q&A session.

    Session objectives:

    To highlight

    • The role and importance of strategic information in planning and monitoring national responses.

    • The priority actions for countries and role of WHO in supporting countries.

    • The latest data on the global viral hepatitis situation and response.

    • Progress made in integrating civil society in the global viral hepatitis response and on global awareness activities.

    • Country examples demonstrating the important role of strategic information for focused action.

  • Speeding access to innovative hepatitis C products: Unitaid’s key role


    Day: 1 November

    Time: 17:30

    This evening side meeting presents Unitaid’s investment and operating model in the context of the emerging global response to hepatitis C. It will share the results of Unitaid-funded projects related to hepatitis C. It will also explore opportunities for potential future investments. 


    • Opening remarks – Unitaid’s model and its relevance for Hepatitis C.
    • Where are we today?
    • Developing a simplified mode of care for HCV.
      Anne Loarec, Médicins Sans Frontère
    • Creating demand and innovative solutions for access to HCV treatment.
      Khalil Elouardighi, Coalition Plus
    • Facilitating access to HCV treatment through voluntary licensing
      Greg Perry, Medicines Patent Pool
    • Facilitating diagnostic solutions
      Francesco Marinucci, FIND
    • Putting the pieces together to maximise benefits.
      Dr. Marc Bulterys, World Health Organization
    • Moderated discussion.